References

Lecanemab in early Alzheimer's Disease

10.1056/nejmoa2212948 · 2023 · External reference

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial

10.1001/jama.2023.13239 · 2023 · External reference

The AHEAD 3-45 study: design of a prevention trial for Alzheimer's disease

10.1002/alz.12748 · 2023 · External reference

Donanemab in preclinical Alzheimer's disease: screening and baseline data from TRAILBLAZER-ALZ 3

10.1002/alz.70662 · 2025 · External reference

10.1016/s1474-4422(26)00246-2 · 2026 · Admitted local publication

10.1016/s1474-4422(26)00285-1 · 2026 · Admitted local publication

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

10.1002/alz.13859 · 2024 · External reference

Alzheimer disease as a clinical–biological construct—an international working group recommendation

10.1001/jamaneurol.2024.3770 · 2024 · External reference

Alzheimer's disease outlook: controversies and future directions

10.1016/s0140-6736(25)01389-3 · 2025 · External reference

Unresolved reference

1968 · External reference

Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study

10.1016/s1474-4422(25)00350-3 · 2025 · External reference

Brain health services for the secondary prevention of cognitive impairment and dementia: opportunities, challenges, and the business case for existing and future facilities

10.1016/j.tjpad.2025.100098 · 2025 · External reference

Dementia prevention in memory clinics: recommendations from the European task force for brain health services

10.1016/j.lanepe.2022.100576 · 2023 · External reference

NIA–AA research framework: toward a biological definition of Alzheimer's disease

10.1016/j.jalz.2018.02.018 · 2018 · External reference

Blood biomarkers to detect Alzheimer disease in primary care and secondary care

10.1001/jama.2024.13855 · 2024 · External reference

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests

10.1093/brain/awae346 · 2025 · External reference

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

10.1001/jamaneurol.2026.1565 · 2026 · External reference

Plasma MTBR–tau243 biomarker identifies tau tangle pathology in Alzheimer's disease

10.1038/s41591-025-03617-7 · 2025 · External reference

Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease

10.1038/s41467-024-47286-5 · 2024 · External reference

Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force

10.1001/jama.2023.24766 · 2024 · External reference

Colorectal cancer screening: an updated modeling study for the US Preventive Services Task Force

10.1001/jama.2021.5746 · 2021 · External reference

Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force

10.1001/jama.2018.10400 · 2018 · External reference

Amyloid-beta pathology and cognitive performance in centenarians

10.1001/jamaneurol.2025.1734 · 2025 · External reference

A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology

10.1038/s41591-025-04080-0 · 2026 · External reference

Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial

10.1001/jama.2025.12923 · 2025 · External reference

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

10.1016/s0140-6736(15)60461-5 · 2015 · External reference

Effect of personalized risk-reduction strategies on cognition and dementia risk profile among older adults: the SMARRT randomized clinical trial

10.1001/jamainternmed.2023.6279 · 2024 · External reference

2025 Alzheimer's disease facts and figures

10.1002/alz.70235 · 2025 · External reference

Caregivers’ attitudes toward blood-based biomarker testing for Alzheimer's disease

10.1002/dad2.12549 · 2024 · External reference

Research participant interest in learning results of biomarker tests for Alzheimer disease

10.1001/jamanetworkopen.2025.2919 · 2025 · External reference

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

10.1016/s1474-4422(23)00447-7 · 2024 · External reference

The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care

10.1002/alz.14337 · 2025 · External reference

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

10.1016/s0140-6736(24)01296-0 · 2024 · External reference

Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force

10.1001/jama.2022.12138 · 2022 · External reference

Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis

10.1016/j.jacc.2007.06.063 · 2008 · External reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

10.1056/nejmoa052306 · 2005 · External reference

Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

10.1056/nejmoa1601277 · 2017 · External reference

Trial of solanezumab in preclinical Alzheimer's disease

10.1056/nejmoa2305032 · 2023 · External reference

Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies

10.14283/jpad.2024.122 · 2024 · External reference

Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease

10.1001/jamaneurol.2024.3937 · 2025 · External reference

Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials

10.1001/jamaneurol.2025.0065 · 2025 · External reference

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction

10.1002/alz.70062 · 2025 · External reference

Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease

10.1038/s41467-023-43933-5 · 2023 · External reference

Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke

10.1056/nejmc2215148 · 2023 · External reference

Person-specific contribution of neuropathologies to cognitive loss in old age

10.1002/ana.25123 · 2018 · External reference

Lecanemab for early Alzheimer's disease: appropriate use recommendations from the French federation of memory clinics

10.1016/j.tjpad.2025.100094 · 2025 · External reference

An International Working Group viewpoint on stratifying risk and prevention of the clinical expression of Alzheimer's disease

10.1038/s43587-025-00977-0 · 2025 · External reference

Advances in Alzheimer's disease research over the past two decades

10.1016/s1474-4422(22)00298-8 · 2022 · External reference

Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial

10.1001/jamaneurol.2022.3392 · 2022 · External reference

Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers

10.1038/s41591-025-03965-4 · 2025 · External reference

A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease

10.1038/s41746-025-01583-5 · 2025 · External reference

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial

10.1002/alz.13803 · 2024 · External reference

Development and validation of the American Heart Association's PREVENT equations

10.1161/circulationaha.123.067626 · 2023 · External reference

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

2014 · External reference

What's new in dementia risk prediction modelling? An updated systematic review

2024 · External reference

Passive digital markers for Alzheimer's disease and other related dementias: a systematic evidence review

10.1111/jgs.18426 · 2023 · External reference

Development and validation of eRADAR: a tool using EHR data to detect unrecognized dementia

10.1111/jgs.16182 · 2020 · External reference

The electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR) brain health trial: protocol for an embedded, pragmatic clinical trial of a low-cost dementia detection algorithm

10.1016/j.cct.2023.107356 · 2023 · External reference

External validation of the eRADAR risk score for detecting undiagnosed dementia in two real-world healthcare systems

10.1007/s11606-022-07736-6 · 2023 · External reference